40.42

3.56% -1.49

Revolution Medicines Inc (RVMD)

Overview News Price History Option Chain Financials Why RVMD Down? Discussions Forecast

Revolution Medicines Inc stock is traded at $40.42, with a volume of 1.62M. It is down -3.56% in the last 24 hours and up +15.09% over the past month. Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Previous Close:

$41.91

Open:

$41.91

24h Volume:

1.62M

Relative Volume:

0.96

Market Cap:

$7.57B

Revenue:

$29.52M

Net Income/Loss:

$-567.06M

P/E Ratio:

-11.04

EPS:

-3.66

Net Cash Flow:

$-551.11M

1W Performance:

-0.74%

1M Performance:

+15.09%

6M Performance:

-33.12%

1Y Performance:

+7.93%

1-Day Range:

$40.19

$42.24

1-Week Range:

$36.36

$43.67

52-Week Range:

$29.17

$62.40

Revolution Medicines Inc Stock (RVMD) Company Profile

Name

Revolution Medicines Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

415-766-3638

Address

700 SAGINAW DR, REDWOOD CITY, CA

Employee

534

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

RVMD's Discussions on Twitter

Compare RVMD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RVMD Revolution Medicines Inc	40.42	7.57B	29.52M	-567.06M	-551.11M	-3.66
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-16-24	Reiterated	Needham	Buy
Jul-12-24	Initiated	Barclays	Overweight
Jul-08-24	Initiated	Jefferies	Buy
Apr-12-24	Reiterated	Needham	Buy
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy
Mar-11-24	Initiated	Piper Sandler	Overweight
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy
Jan-04-24	Initiated	Wedbush	Outperform
Nov-16-23	Initiated	Raymond James	Outperform
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight
Dec-14-22	Initiated	Needham	Buy
Oct-21-22	Initiated	Oppenheimer	Outperform
May-20-22	Initiated	BofA Securities	Neutral
Mar-01-22	Upgrade	Stifel	Hold → Buy
Sep-23-21	Initiated	Stifel	Hold
Aug-12-21	Downgrade	Goldman	Buy → Neutral
May-18-21	Initiated	Goldman	Buy
May-21-20	Initiated	H.C. Wainwright	Buy
Mar-09-20	Initiated	Cowen	Outperform
Mar-09-20	Initiated	Guggenheim	Buy
Mar-09-20	Initiated	JP Morgan	Neutral

View All

Revolution Medicines Inc Stock (RVMD) Latest News

09:46 AM

We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth - Yahoo Finance

09:46 AM

May 08, 2025

Revolution medicines outlines 2025 focus on RAS(ON) inhibitors in key cancer trials - MSN

May 08, 2025

Revolution Medicines’ Earnings Call: Optimism Amid Rising Costs - TipRanks

May 08, 2025

RVMD: Guggenheim Maintains Buy Rating, Lowers Price Target to $8 - GuruFocus

May 08, 2025

The Lustgarten Foundation Honors Revolution Medicines for Transformative Research in Pancreatic Cancer - Yahoo Finance

May 08, 2025

Oppenheimer Raises Price Target for RVMD, Maintains Outperform Rating | RVMD Stock News - GuruFocus

May 08, 2025

RVMD: Guggenheim Maintains Buy Rating, Lowers Price Target to $80 | RVMD Stock News - GuruFocus

May 08, 2025

RVMD Price Target Lowered but Buy Rating Maintained by Guggenheim | RVMD Stock News - GuruFocus

May 08, 2025

Revolution Medicines (RVMD) Target Price Raised Amid Positive Outlook | RVMD Stock News - GuruFocus

May 08, 2025

Needham Reiterates Buy Rating for Revolution Medicines (RVMD) | RVMD Stock News - GuruFocus

May 08, 2025